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Abstract
Background: Rett syndrome (RTT) is a neurological disorder mainly caused by mutations in MeCP2 gene. It has
been shown that MeCP2 impairments can lead to cytokine dysregulation due to MeCP2 regulatory role in T-helper
and T-reg mediated responses, thus contributing to the pro-inflammatory status associated with RTT. Furthermore,
RTT subjects suffer from an intestinal dysbiosis characterized by an abnormal expansion of the Candida population,
a known factor responsible for the hyper-activation of pro-inflammatory immune responses. Therefore, we asked
whether the intestinal fungal population of RTT subjects might contribute the sub-inflammatory status triggered by
MeCP2 deficiency.
Methods: We evaluated the cultivable gut mycobiota from a cohort of 50 RTT patients and 29 healthy controls
characterizing the faecal fungal isolates for their virulence-related traits, antifungal resistance and immune reactivity
in order to elucidate the role of fungi in RTT’s intestinal dysbiosis and gastrointestinal physiology.
Results: Candida parapsilosis, the most abundant yeast species in RTT subjects, showed distinct genotypic profiles if
compared to healthy controls’ isolates as measured by hierarchical clustering analysis from RAPD genotyping. Their
phenotypical analysis revealed that RTT’s isolates produced more biofilm and were significantly more resistant to
azole antifungals compared to the isolates from the healthy controls. In addition, the high levels of IL-1β and IL-10
produced by peripheral blood mononuclear cells and the mixed Th1/Th17 cells population induced by RTT C.
parapsilosis isolates suggest the capacity of these intestinal fungi to persist within the host, being potentially
involved in chronic, pro-inflammatory responses.
Conclusions: Here we demonstrated that intestinal C. parapsilosis isolates from RTT subjects hold phenotypic traits
that might favour the previously observed low-grade intestinal inflammatory status associated with RTT. Therefore,
the presence of putative virulent, pro-inflammatory C. parapsilosis strains in RTT could represent an additional factor
in RTT’s gastrointestinal pathophysiology, whose mechanisms are not yet clearly understood.
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Background
The gut mycobiota, together with the bacterial micro-
biota, exerts key roles in maintaining the intestinal mi-
crobial community structure, metabolic functions and
has strong immunomodulatory properties, being a
main actor in host physiopathology [1]. The host re-
sponse to fungi is mediated at first by the innate
immunity through recognition of the fungal pathogen-
associated molecular patterns (PAMPs) by the host
cells’ pattern recognition receptors (PRRs). The C-type
lectin receptors (CLRs; e.g. dectin 1 and dectin 2, also
known as CLEC7A and CLEC6A respectively) are fun-
damental for fungal recognition and for the develop-
ment of innate and adaptive immune responses,
especially T-helper (Th) 1 and Th17 responses [2]. Th1
cells, through the production of IFNγ and TNFα, acti-
vates and recruits phagocytes (macrophages, neutro-
phils) at potential sites of infection [2], while Th17
cells are necessary for protection against fungal infec-
tions [3, 4]. In fact, IL-17 ability to mobilize neutro-
phils and to induce the production of antimicrobial
peptides contributes to an efficient control of fungi at
different body sites [2]. However, well balanced pro-
inflammatory and tolerogenic responses are a pre-
requisite to avoid potential harmful inflammatory
responses triggered by gastrointestinal fungi. The shift
between pro-inflammatory and tolerogenic dendritic
cells (DCs) responses are mediated by the kynurenine
pathway of tryptophan catabolism, in which the ex-
pression of indoleamine 2,3-dioxygenase (IDO1) has a
key role on plasticity of DCs activities in balancing be-
tween CD4+ effector Th cells and regulatory T (T-reg)
cells [2, 5]. IDO1 is widely recognized as a regulator of
immune homeostasis and suppressor of inflammation
by inducing IL-10 through the production of immune-
active kynurenines that activate the aryl-hydrocarbon
receptor (AHR) in lymphoid tissues [6], thus inducing
the transcription of FOXP3 and promoting immune
tolerance via T-reg cells [7, 8]. Nevertheless, the mech-
anisms by which commensal fungi choose to shift their
phenotype towards infection are not well understood,
even if the disruption of the microbial community
structure resulting in intestinal dysbiosis has been pro-
posed to be one of the reasons [9]. Indeed, alterations
of the gut microbiota can lead to inflammation involv-
ing hyper activation of Th1 and Th17 immune re-
sponses [10]. Altered immunological response to fungi
can in turn contribute to systemic inflammatory re-
sponses. Remarkably, fungal infections shift IDO1’s ac-
tivity [11, 12], reducing the levels of kynurenine and
thus promoting inflammation [13]. Furthermore, alter-
ations of the levels of kynurenine, a neuroprotective
agent, have been implicated in several pathologies, in-
cluding autism spectrum disorders [14].
Rett syndrome (RTT) is a neurological disorder that al-
most exclusively affects females with an incidence of 1:
10,000 live births [15] due to a loss-of-function mutations
of the X-linked methyl-CpG binding protein 2 (MeCP2)
gene in approximately 90% of classic RTT cases [16]. RTT
subjects develop normally up to 18 months of age after
which they undergo a period of neurological regression
[15]. RTT affects several organs and systems among which
the autonomic nervous system [15], the gastrointestinal
tract [17] and the immune system [18] making it eligible
as a multisystemic disease [15]. It has been shown that
MeCP2 deficiency is able to lead to cytokine dysregulation
[18, 19], to influence the expression of FOXP3 [20], an im-
portant transcription factor involved in the generation of
T-reg cells, and to determine the significant increase of se-
creted IL-17A [20]. Since the Th17/T-reg balance is impli-
cated in the development of autoimmune/inflammatory
disorders it is possible to hypothesize the presence of an
autoimmune component in RTT [21]. To this regard, in-
testinal dysbiosis may cause chronic intestinal inflamma-
tion and autoimmunity as occurring in Inflammatory
Bowel Diseases (IBDs) [22]. Previous studies indicated the
presence of a subclinical inflammatory status in subjects
affected by RTT [23] remarked by cytokine dysregulation
in both Th1 and Th17 responses [19, 20, 24, 25] and an in-
testinal dysbiosis characterized by high relative abundance
of the genus Candida [26]. Therefore, we asked whether
the intestinal fungal population of RTT subjects might be
involved in the sub-inflammatory status triggered by
MeCP2 deficiency. Here we studied the cultivable gut
mycobiota of RTT subjects characterizing the isolated
fungi for their virulence-related traits and antifungal re-
sistance. Moreover, we characterized the genetic diversity
of C. albicans and C. parapsilosis isolates and their ability
to induce innate and adaptive immunological responses in
human PBMCs in order to elucidate the role of fungi in
RTT gastrointestinal pathophysiology.
Methods
Isolation and identification of cultivable fungal species
from faeces
The participants’ data related to the 50 RTT patients and
29 Healthy Controls (HC) included in this study are avail-
able in [26]. Stool samples from enrolled subjects [26] were
collected, aliquoted as it is and stored at − 80 °C until ana-
lysis. Samples were homogenized in sterile Ringer’s solution
and plated on solid YPD medium (1% Yeast extract, 2%
Bacto-peptone, 2% D-glucose, 2% agar) supplemented with
25 U/ml of penicillin, 25 μg/ml of streptomycin (Sigma-Al-
drich) and incubated aerobically at 27 °C for 3–5 days. All
fungal isolates grown on the selective medium were further
isolated to obtain single-cell pure colonies. Genomic DNA
was extracted from pure cultures of the isolated colonies as
previously described [27]. Fungal isolates were identified by
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amplification and sequencing of the ribosomal Internal
Transcribed Spacer (ITS) region, using ITS1 (5’-
GTTTCCGTAGGTGAACTTGC-3′) and ITS4 (5’-
TCCTCCGCTTATTGATATGC-3′) primers [28]. ITS1–4
sequences were then classified by using the BLAST algo-
rithm in the NCBI database (minimum 97% sequence simi-
larity and 95% coverage with a described species).
Invasive growth
The ability of fungal strains to penetrate YPD solid
medium was tested as previously described [29]. M28-
4D and BY4742 S. cerevisiae strains, known to be inva-
sive and non-invasive respectively, were used as controls.
The strain invasiveness was assigned with scores from 3
(highly invasive) to 0 (non-invasive).
Hyphal formation
Fungal cells (~ 105 cells/ml) were grown for 7 days in liquid
YPD and YNB media (0.67% Yeast Nitrogen Base w/o
aminoacids and (NH4)2SO4 (Sigma-Aldrich), 2% glucose),
both at 27 °C and 37 °C in order to evaluate hyphae or
pseudohyphae formation. Formation of hyphae was
inspected by optical microscope observation with a Leica
DM1000 led instrument (magnification 40× and 100×) [30].
Biofilm formation
Biofilm formation was quantified according to a previous
published protocol [31]. Briefly, fungal cells (~ 105 cells/
ml) were grown in liquid YPD at 37 °C for 48 h in flat-
bottom 96-well plates. After the incubation period, cell
suspensions were aspirated and each well with the ad-
hered fungal cells was washed three times with deion-
ized H2O and one time with PBS 1X. Biofilm-coated
wells were then incubated with 0.01% of crystal violet
(Sigma) for 30 min and washed as above. Finally, each
well of the dried 96-well plate was incubated with 100 μl
of 100% EtOH for 10 min and biofilm formation was
quantified by optical density measurement at 570 nm
with a microplate reader (Synergy2, BioTek, USA).
Antifungal susceptibility testing
All fungal isolates were tested for susceptibility to flu-
conazole, itraconazole and 5-flucytosine (Sigma-Al-
drich) by Minimum Inibitory Concentration (MIC)
assays according to the European Committee on Anti-
microbial Susceptibility Testing (EUCAST) recommen-
dations [32, 33]. EUCAST clinical breakpoints (CBPs)
were used to evaluate the antifungal resistance. Al-
though CBPs have not been established for non-Can-
dida yeasts and the non-Aspergillus moulds, they have
been used as a proxy for the evaluation of antifungals
susceptibility in such isolates.
RAPD genotyping and clustering analysis
Candida albicans and C. parapsilosis isolates were geno-
typed by Random Amplification of Polymorphic DNA
(RAPD) using the primer Oligo 2 (5’-TCACGATGCA-3′)
as described previously [34]. Amplifications were per-
formed according to the following protocol: 5 min at 94 °C,
40 cycles of 30s at 94 °C, 30s at 36 °C and 2 min at 72 °C,
followed by a final extension of 10 min at 72 °C. The PCR
reaction mix contained 1X PCR buffer 2 mM MgCl2,
200 μM of dNTPs, 0.4 μM of the primer, 2.5 U of Taq Poly-
merase and 10 ng of gDNA as template. PCR amplicons
were separated using a 2% agarose gel in 1× TAE buffer at
90 V for 2 h and visualized with 0.5 μg/ml ethidium brom-
ide staining. The presence or absence of an amplicon at any
position of the gel was used for the construction of a binary
matrix for the calculation of samples’ distance similarity ac-
cording to the Jaccard index [35] by mean of the “vegdist”
function within the vegan R package. The samples have
been then clustered hierarchically according to the
UPGMA method by using the “hclust” function within the
stats R package.
Isolation and stimulation of PBMCs
Human peripheral blood mononuclear cells (PBMCs) were
isolated by Ficoll-Hypaque density gradient centrifugation
(Biochrom, Berlin, Germany) from buffy coats provided by
the Transfusion Unit of Ospedale Santa Chiara in Trento,
Italy. The experimental plan was approved by the local
hospital ethical committee, and informed consent was
obtained from all the healthy donors (protocol No:
54896583). Candida isolates were cultured in YPD
medium for 18 h at 37 °C. Fungal cells were harvested by
centrifugation, washed twice with PBS, heat-killed for 3 h
at 65 °C and resuspended in culture medium (RPMI1640;
Sigma Aldrich). For stimulation experiments, 5 × 105
PBMCs in RPMI1640 were incubated with 5 × 106 heat-
killed C. albicans, C. parapsilosis or RPMI1640 medium
alone (negative control) [36]. After the incubation periods
(24 h for IL-1β, IL-6, TNF-α, IL-10 production and 120 h
for IL-17A, INFγ, IL-22, IL-10 production) cell suspensions
were centrifuged and supernatants were collected and
stored at − 20 °C until assayed. Each experiment was per-
formed in triplicate.
Cytokine assays
Cytokine detection i.e. IL-17A, INFγ, IL-22, IL-1β, IL-6,
TNF-α, IL-10 production, were assayed using the MAP hu-
man cytokine/chemokine kit (Merck Millipore) according
to the manufacturer’s instructions (MagPix technology).
Flow cytometry
PBMCs were collected after stimulation with Candida
isolates in a ratio of 10:1 (stimuli:cells) and washed with
PBS. Intracellular staining for IDO1 (after 24 h of
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stimulation), T-bet and RORγt (after 5 day of stimula-
tion) were performed using the fixation/permeabilization
buffer kit (Life Technologies) following the manufactur-
ing recommendations. Cells were then stained with ad-
equate concentrations of labelled antibodies diluted in
PBS with 10% heat-inactivated foetal bovine serum (FBS)
for 20 min at room temperature, A minimum of ten
thousand events for each sample were acquired using a
Guava easyCyte 8 T flow cytometer (Merck Millipore)
and analysed using the inCyte software (Merck Milli-
pore). Cells were gated first based on forward and side
scatter to exclude dead cells and cell debris. The area of
positivity was determined by using an isotype-matched
control MAb. Antibodies used: Fluorescein isothiocyan-
ate (FITC)-IDO1 (BD Biosciences Pharmingen, Prodotti
Gianni, Italy), FITC-Tbet (Millipore), allophycocyanin
(APC)-RORγt (BD Biosciences Pharmingen, Prodotti
Gianni, Italy).
Statistical analysis
Wilcoxon rank-sum tests and Spearman’s correlations
were performed using the R software [37] through the
stats R package (version 3.1.2) and the psych R package,
respectively. Permutational MANOVA (PERMANOVA)
test was performed using the adonis()function of the
vegan R package with 999 permutations. All p-values
have been corrected for multiple hypothesis controlling
the false discovery rate (FDR) [38].
Results
RTT gut mycobiota shows a reduction of C. albicans and
an increase of C. parapsilosis populations
We identified 122 fungal isolates belonging to different
species (Additional file 1: Table S1). Twenty-four of such
isolates were obtained from stool samples of RTT subjects
(Additional file 1: Table S1). We discovered a significant
reduction of fungal species richness in RTT subjects com-
pared to HC (p = 3.9e-05, Wilcoxon rank-sum test) in
agreement with the results obtained using a metagenomic
approach from the same study cohort [26]. Candida was
the most abundant genus present in both RTT subjects
(91.7%) and HC (71.4%) with C. albicans and C. parapsilo-
sis as the two most abundant species in both RTT subjects
and HC. Interestingly, we observed an inversion in the
relative abundances of C. albicans and C. parapsilosis be-
tween RTT subjects and HC. While in RTT subjects 4 out
of 24 fungal isolates belonged to C. albicans (16.7%) and
14 out of 24 belonged to C. parapsilosis (58.3%), in the
HC 49 out of 98 fungal isolates belonged to C. albicans
(50%) and 15 out of 98 belonged to C. parapsilosis (15.3%)
(Additional file 2: Figure S1). We then characterized the
fungal isolates for putative virulence-associated traits and
resistance to antifungals (Additional file 1 Table S1). We
found that 50% and 63.8% of fungal isolates from RTT
subjects and HC, respectively, were able to form hyphae
or pseudohyphae (Additional file 1: Table S1). In addition,
we observed that the morphotype switch to hyphae or
pseudohyphae was related to the isolates’ invasiveness,
with hyphae- and pseudohyphae-forming isolates being
the most invasive (Additional file 3: Figure S2A). We also
observed that RTT isolates produced more biofilm (p = 1.
3e-05, Wilcoxon rank-sum test; Additional file 3: Figure
S2B) and were significantly more resistant to fluconazole
compared to HC isolates (45.8% of RTT isolates were re-
sistant vs 18.1% of HC isolates; p = 5.1e-06, Wilcoxon
rank-sum test). As previously observed, we found the co-
occurrence of azole cross-resistance between fluconazole
and itraconazole (Spearman’s correlation r = 0.57; p = 2.2e-
10) [39]. Almost the totality of the isolates (96.7%) were
susceptible to 5-flucytosine, with MIC≤0.125 μg/ml (Add-
itional file 1: Table S1). Candida parapsilosis isolates from
HC were susceptible to fluconazole (MIC90 = 2 μg/ml; R =
7.1%) and itraconazole (MIC90 = 0.0156 μg/ml; R = 0%)
while C. parapsilosis isolates from RTT subjects exhibited
a high resistance to these antifungals (fluconazole,
MIC90 > 64 μg/ml, R = 35.7%, p = 0.003, Wilcoxon rank-
sum test, Figure 1A; itraconazole, MIC90 > 8 μg/ml, R =
35.7%; Table 1). On the contrary, C. albicans isolates from
HC were resistant to fluconazole (MIC90 > 64 μg/ml, R =
24.4%) and itraconazole (MIC90 > 8 μg/ml, R = 63.4%; p =
0.03, Wilcoxon rank-sum test; Fig. 1B) while only one
RTT C. albicans isolate was resistant to fluconazole (Table
1). Noteworthy, all other Candida species isolated from
RTT subjects (i.e. C. glabrata, C. pararugosa and C. tropi-
calis) were resistant to fluconazole (MIC90 > 64 μg/ml; R
= 100%) and itraconazole (MIC90 = 8 μg/ml; R = 100%)
while Candida spp. isolated from HC (i.e. C. deformans,
C. intermedia and C. lusitaniae) were completely suscep-
tible to these azoles (Table 1). Taken together these results
suggest that RTT isolates may be more difficult to eradi-
cate in case of infection than HC isolates. Finally, we have
been able to isolate Trichosporon asteroides and Saccharo-
myces cerevisiae only from RTT subjects. These isolates
were both resistant to fluconazole (with MIC>64 μg/ml
and MIC= 8 μg/ml respectively) while Trichosporon aster-
oides was also resistant to itraconazole (MIC>8 μg/ml).
Such species are recognized as potential new emerging
fungal pathogens [40] thus representing a potential threat
for RTT subjects.
C. parapsilosis isolates from RTT subjects and HC are
genetically distinct
The genetic diversity among Candida isolates was deter-
mined by UPGMA hierarchical clustering analysis of Jac-
card distances calculated from RAPD genotyping. We
observed that C. parapsilosis isolates from RTT samples
were genetically unrelated to those from HC, with most
of RTT C. parapsilosis isolates clustering in a single
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group (Fig. 2 and Additional file 4: Figure S3; p = 0.002,
PERMANOVA). On the contrary, C. albicans isolates
from RTT subjects were genetically more diverse, clus-
tering in different clades of the tree (Additional file 5:
Figure S4; p = 0.779, PERMANOVA). It is worth noting
that we only obtained 4 C. albicans isolates from RTT
samples.
Candida parapsilosis from RTT subjects induces high
levels of IL-10 in PBMCs
The first step in the immunological response against Can-
dida is the production by innate immune cells of pro-
inflammatory cytokines, such as IL-1β, IL-6 and TNFα.
Successively, these cytokines promote adaptive immunity
mediated by Th1 or Th17 responses [2]. Stimulation of
PBMCs with C. albicans and C. parapsilosis isolates from
HC and RTT subjects revealed that RTT Candida para-
psilosis isolates induced higher levels of IL-1β (p = 0.01,
Wilcoxon rank-sum test) and, although only close to
statistical significance, TNFα (p = 0.058, Wilcoxon rank-
sum test) with respect to HC Candida parapsilosis isolates
(Fig. 3). On the contrary, no significant differences were
observed in the levels of IL-17A, IL-22 and INFγ (Fig. 3).
Furthermore we observed that C. parapsilosis isolates
from RTT subjects induced highly significant levels of IL-
10 compared to HC C. parapsilosis isolates and RTT C.
albicans isolates (p < 0.003, Wilcoxon rank-sum test;
Fig. 3) suggesting an increased fungal tolerance towards
these C. parapsilosis isolates, potentially favouring fungal
persistence within the host. Nevertheless, we did not ob-
serve significant differences in the expression of IDO1 in
PBMCs stimulated by C. parapsilosis isolates (median HC
= 30%, IQR = 22.8–39.3%; median RTT = 44%, IQR = 29.
1–48.3%; p = 0.24, Wilcoxon rank-sum test). Since we
observed variable levels of Th-driving cytokines, we asked
whether Candida isolates were able to induce a different
Th1/Th17 polarization. Therefore, we measured the intra-
cellular levels of the key transcription factors T-bet and
RORγt (Additional file 6: Figure S5), involved in the differ-
entiation of CD4+ naïve cells in Th1 and Th17 cell,
respectively [41]. As previously observed in culture
supernatants, we measured variable, but not statistically
a b
Fig. 1 a) Fluconazole and b) itraconazole resistance as measured by MIC values in C. albicans and C. parapsilosis isolates from HC and RTT
subjects. MIC values are reported as means ± standard errors. Exact p-values are reported and considered significant if < 0.05
Table 1 Antifungals resistance of Candida isolates from HC or RTT patients
Species Antifungals Healthy controls (HC) Rett syndrome (RTT) subjects
MIC (μg/ml) aCBPs MIC (μg/ml) aCBPs
MIC50 MIC90 %S %R MIC50 MIC90 %S %R
C. albicans Fluconazole 0.5 > 64 75.6 24.4 1 2 75 25
Itraconazole 0.25 > 8 36.6 63.4 0.0156 0.0156 100 0
5-Flucytosine 0.125 0.5 97.6 2.4 0.125 0.125 100 0
C. parapsilosis Fluconazole 0.5 2 92.9 7.1 2 > 64 64.3 35.7
Itraconazole 0.0156 0.125 100 0 0.0156 > 8 64.3 35.7
5-Flucytosine 0.125 0.5 100 0 0.125 0.125 100 0
bCandida spp. Fluconazole 0.125 0.25 100 0 > 64 > 64 0 100
Itraconazole 0.0156 0.0156 100 0 8 8 0 100
5-Flucytosine 0.125 0.125 100 0 0.125 0.125 100 0
aAccording to EUCAST recommendations; S sensible; R Resistant; MIC ranges: Fluconazole 0.125–64 μg/ml; Itraconazole 0.0156–8 μg/ml; 5-Flucytosine 0.125–
64 μg/ml. bCandida spp. isolated from RTT subjects (i.e. C. glabrata, C. pararugosa and C. tropicalis); Candida spp. isolated from HC (i.e. C. deformans, C. intermedia
and C. lusitaniae)
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significant levels of T-bet and RORγt in response to the
different C. parapsilosis and C. albicans isolates (Add-
itional file 6: Figure S5), reflecting the potential of different
strains to elicit an immune reaction at different extents.
This could be due to the diverse immune reactivity shown
by the different isolates of the same species, as previously
reported [42, 43]. However, C. parapsilosis isolates from
RTT subjects induced more CD4+ cells co-expressing both
RORγt and T-bet compared to HC C. parapsilosis isolates
(raw p-value = 0.04, FDR-corrected p-value = 0.12; Wil-
coxon rank-sum test; Additional file 6: Figure S5c).
Discussion
In the present study we show that in RTT, a multisystemic
neurological disorder, faecal C. parapsilosis isolates hold
phenotypic traits potentially favouring the previously ob-
served low-grade intestinal inflammatory status [26].
Species-level analysis of the cultivable gut mycobiota re-
vealed C. parapsilosis as the most abundant yeast species in
RTT subjects, genetically distinct from HC C. parapsilosis
isolates. Interestingly, RTT C. parapsilosis isolates were
characterized by high levels of resistance to azoles antifun-
gals. Furthermore, the high levels of IL-10 produced by
PBMCs in response to RTT C. parapsilosis isolates suggest
that these isolates have developed the capacity to persist
within the host. IL-10 usually exert a homeostatic control to
keep inflammation under control, although high levels of
IL-10 are characteristic of chronic fungal infections
dominated by non-resolving inflammation [2]. It has been
observed that C. albicans induces host’s immunosuppres-
sion by increased IL-10 production by immune cells
representing an important mechanisms in Candida patho-
genesis [44]. Likewise, RTT C. parapsilosis isolates could es-
cape immune clearance through a mechanism mediated by
high levels of IL-10 that, in turn, could impair antifungal
Th1 immunity, thus favouring a persistent intestinal
colonization.
Fig. 2 Multidimensional scaling analysis of C. parapsilosis genetic
diversity calculated by UPGMA hierarchical clustering analysis of
samples’ distance similarities (Jaccard index) from RAPD genotyping.
C. parapsilosis isolates from HC and RTT subjects in green and
red, respectively
a b
c d
e f
g h
Fig. 3 Cytokines production by peripheral blood mononuclear cells
(PBMCs; 5 × 105 cell) after stimulation with 5 × 106 heat-killed C.
albicans or C. parapsilosis isolates from HC and RTT subjects. In panels
a-d) are reported the values for the cytokines produced by innate
immune cells (IL-1β, IL-6, TNFα and IL-10 after 24 h of PBMCs stimulation)
while in e-h) the values for the cytokines produced following adaptive
immune responses (IL-17A, IL-22, IFNγ and IL-10 after 5 days of PBMCs
stimulation). The dots represent each of the three replicates per isolate
tested; *p< 0.05, Wilcoxon rank-sum test
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C. parapsilosis has been described as one of the leading
causes of invasive candidiasis [45], being responsible of
macrophage activation and allergic airways inflammation
[46] and to be one of the dominant Candida species lead-
ing to dysbiosis in IBDs [47]. Fungal opportunistic infec-
tions are generally ascribed to defective host immunity,
although they could require specific microbial population
dysbiosis [48], as recently observed in RTT [26]. Recent
studies indicated that fungal infections may originate from
individual’s own commensal strains and that the ability of
a commensal organism to produce disease is not merely a
consequence of impaired host immunity [49]. Indeed, C.
albicans passage through the GI tract results in a pheno-
typic switch in the so-called gastrointestinal induced tran-
sition cells, where virulence-associated genes are down-
regulated enabling fungal adaptation for long-term sur-
vival in the large intestine [50]. Recent studies further
show how strain specific differences in morphogenetic
networks, regulating the switch from hyphal and yeast
forms, subtend differences in their pathogenic potential,
thus suggesting the importance to move the metage-
nomics analyses to the strain level [51]. Therefore, C.
parapsilosis isolates from RTT subjects may be commen-
sals potentially hazardous for the host due not only to
RTT’s altered immunological status [19] but also by the
presence of a dysbiotic gut microbiota [26]. Moreover,
RTT C. parapsilosis isolates induced a higher proportion
of a mixed Th1/Th17 cells population compared to HC C.
parapsilosis isolates. Although Th1 and Th17 responses
usually counter-regulate each other, there are increasing
evidences of co-operation and dependency between these
two immunological responses [52] which are involved in
chronic, pro-inflammatory responses as observed in IBDs
[53] potentially resulting in adaptive immunity against the
commensal microbiota [54]. Interestingly, it has been pre-
viously shown that MeCP2 could actually play a regulatory
role in T-cell resilience to inflammation [20]. Emerging
evidence indicates that MeCP2 deficiency is able to lead to
cytokine dysregulation including macrophage-related cy-
tokines in Mecp2-null mice and RTT females [18, 19], al-
though the understanding of the molecular mechanisms
underlying this pro-inflammatory status remains elusive.
We have previously evidenced an inflammatory process
in both RTT patients [19, 23] and animal models [55]. Bio-
chemical analyses showed significant changes in the expres-
sion of acute phase response (APR) and immune system
proteins in the serum of RTT subjects [23]. A direct rela-
tionship between MeCP2 and the immune system has been
demonstrated, since MeCP2 is important for the differenti-
ation of naïve CD4+ T cells into Th17 cells and for the
commitment of naïve CD4+ T cells to the Th1 lineage [24].
Indeed, MeCP2 plays a critical role in promoting multiple
cytokine-mediated signalling pathways through the
MeCP2-miR-124-SOCS5 axis. This signalling pathway is
required for the activation of signal transducer and activa-
tor of transcription 3 (STAT3) and STAT1 in CD4+ T cells,
with consequent generation of Th17 cells [24]. The
mechanisms underlying the inflammatory process appear
to be related to a severe cytokine dysregulation, possibly
reflecting a macrophage dysregulation/dysfunction, as
previously suggested for Mecp2−/− mice [56]. Furthermore,
there is a critical interplay between inflammation and
oxidative stress in the underlying mechanisms [57]. More
recently, MeCP2 has been reported to act as an epigenetic
regulator of immune and inflammatory responses during
zebrafish development [58]. In this context, the bacterial
and fungal microbiota dysbiosis demonstrated in our
previous metataxonomics study from the same cohort of
subjects [26] and the presence of putative virulent, pro-
inflammatory intestinal C. parapsilosis strains could
represent an additional factor in RTT’s gastrointestinal
pathophysiology and subclinical inflammation.
Conclusions
The gut mycobiota is emerging as a key player in main-
taining the overall microbial community structure of the
human gut, and main actor in host physiopathology
[59]. Previous observations from our team indicated the
presence of a subclinical inflammatory status [23], cyto-
kine dysregulation [19] and intestinal dysbiosis [26] con-
tributing to gastrointestinal symptoms in Rett syndrome.
In the present manuscript, we moved our analysis to the
strain level, investigating whether fungal isolates from
RTT subjects may favour the sub-inflammatory status
triggered by MeCP2 deficiency. Our results discovered
C. parapsilosis, but not C. albicans, as the most abun-
dant and potentially pro-inflammatory yeast species in
the gut of RTT subjects. We propose that intestinal dys-
biosis and the presence of pro-inflammatory C. parapsi-
losis strains could have a role in RTT’s gastrointestinal
abnormalities laying the basis for the design of novel
therapeutic strategies that, by targeting specific compo-
nents of the gut microbiota, would restore eubiosis and
intestinal physiology in RTT.
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